Please assess the completion status of the following clinical trial:

Trial Title: PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the subject~2. Healthy male subjects~3. Age between 18 and 64 years, both inclusive~4. Body Mass Index (BMI) between 18.5 and 29.0 kg/m\^2, both inclusive~5. Fasting plasma glucose concentration \<= 5.50 mmol/L (100 mg/dL) at screening~6. Considered generally healthy upon completion of medical history, physical examination, vital signs, ECG and analysis of laboratory safety variables, as judged by the Investigator~Exclusion Criteria:~1. Known or suspected hypersensitivity to investigational medicinal products (IMPs) or related product~2. Previous participation in this trial. Participation is defined as randomized~3. Use of other investigational drugs within five half-lives for enrolment or receipt of any medicinal product in clinical development within 30 days before randomization in this trial, whichever is longer~4. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.~5. Clinically significant abnormal values for haematology, biochemistry, coagulation, or urinalysis as judged by the Investigator~6. Increased risk of thrombosis, e.g subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator~7. A positive result in the alcohol and/or urine drug screen at the screening visit~8. Positive to the screening test for Hepatitis Bs antigen or Hepatitis C antibodies and/or a positive result to the test for HIV-1/2 antibodies or HIV-1 antigen~9. Blood donation or blood loss of m ore than 500 mL within the last 3 months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Gan & Lee Insulin Aspart (Type: EXPERIMENTAL): 100 units/mL, 3 ml prefilled pen
- NovoRapid® Insulin Aspart (Type: ACTIVE_COMPARATOR): Product approved and marketed in the EU~FlexPen100 units/mL prefilled pen
- NovoLog® Insulin Aspart (Type: ACTIVE_COMPARATOR): Product approved and marketed in the US~FlexPen100 units/mL prefilled pen

Based on this trial design, predict the completion outcome and termination type (if applicable).